Ashley Lora joined an eczema clinical trial for DUPIXENT and paved the way for other Black women to try clinical trials.

Soquelitinib Interim Data from the Atopic Dermatitis Phase 1 Clinical Trial As of May 6, 2025, enrollment into cohorts 1 ... risks detailed in the Quarterly Report on Form 10-Q for the first quarter ...

Atopic dermatitis, the most common form of eczema, can lead to dry, itchy, and inflamed skin. It often comes and goes in flares. Atopic dermatitis affects people of all skin tones, but it doesn't ...

The phase 2b trial compared four doses of temtokibart to placebo in 262 adults with moderate to severe atopic dermatitis, the ...

Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis ... like Sanofi and Regeneron’s Dupixent (dupilumab), which dominates ...

New research from the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai ...

CEO Richard Miller emphasized promising Phase 1 trial results for soquelitinib in patients with atopic dermatitis ... to existing treatments like Dupixent and JAK inhibitors.

The company plans to share top-line results from a 400-patient phase 2b study for ResPEG in atopic dermatitis in June ... against key benchmarks like Dupixent. Ideally, we would identify a clear ...

After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the new indication of atopic dermatitis (AD), a common form of eczema.